Drug Profile
NC 164
Latest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Health Protection Agency Porton Down
- Developer Allergan; Health Protection Agency Porton Down
- Class Analgesics
- Mechanism of Action Neurotransmitter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 16 Feb 2005 Discontinued - Preclinical for Pain in United Kingdom (unspecified route)
- 24 Nov 1998 Preclinical development for Pain in United Kingdom (Unknown route)